PR Newswire Clinical TrialsOriginal article
72 patient multi-indication trial approved to fast track TRP-8803 commercialisation
Phase 1positiveTRP-8803Positive
AI Analysis
Summary
Perception Neuroscience obtained HREC approval for a phase 1b/2a basket study of TRP-8803 (psilocin) across eight indications in 72 patients. The world-first trial aims to fast-track commercialization of the IV-infused psilocin candidate for disorders with high unmet treatment needs.
Clinical Trial Data
Phase
1b/2a
Patients
72
Outcome Details
HREC approval secured for phase 1b/2a multi-indication basket study
Importance:6/10
Sentiment:
0.70
HREC approvalbasket studypsilocinpsychedelicsmulti-indicationunmet medical need
Read the original article
Published by PR Newswire Clinical Trials on August 4, 2026 2:00 PM